Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Raymond J. Andersen, Nasrin R. Mawji, Jun Wang, Gang Wang, Simon Haile, Jae-Kyung Myung, Kate Watt, Teresa Tam, Yu Chi Yang, Carmen A. Bañuelos, David E. Williams, Iain J. McEwan, Yuzhou Wang, Marianne D. Sadar

Research output: Contribution to journalArticle

317 Citations (Scopus)

Abstract

Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity.
Original languageEnglish
Pages (from-to)535-546
Number of pages12
JournalCancer Cell
Volume17
Issue number6
Early online date14 Jun 2010
DOIs
Publication statusPublished - 15 Jun 2010

Keywords

  • cellcycle

Fingerprint Dive into the research topics of 'Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor'. Together they form a unique fingerprint.

  • Cite this

    Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., Williams, D. E., McEwan, I. J., Wang, Y., & Sadar, M. D. (2010). Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell, 17(6), 535-546. https://doi.org/10.1016/j.ccr.2010.04.027